Wantai Biotech announced that the clinical trial application for the “recombinant trivalent rotavirus subunit vaccine” declared by its wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. has been accepted by the State Drug Administration. The vaccine is suitable for preventing rotavirus gastroenteritis. It was jointly developed by Xiamen University and Xiamen Wantai Canghai Biotechnology Co., Ltd., and produced using genetic engineering recombination technology and an Escherichia coli expression system. As of November 30, 2025, the company invested about RMB 658.531 million in R&D expenses on this project. The acceptance of this application is an important step forward in the company's innovative vaccine research and development. If the product is successfully developed and listed, it will help enrich the company's product layout and enhance market competitiveness.

Wantai Biotech announced that the clinical trial application for the “recombinant trivalent rotavirus subunit vaccine” declared by its wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. has been accepted by the State Drug Administration. The vaccine is suitable for preventing rotavirus gastroenteritis. It was jointly developed by Xiamen University and Xiamen Wantai Canghai Biotechnology Co., Ltd., and produced using genetic engineering recombination technology and an Escherichia coli expression system. As of November 30, 2025, the company invested about RMB 658.531 million in R&D expenses on this project. The acceptance of this application is an important step forward in the company's innovative vaccine research and development. If the product is successfully developed and listed, it will help enrich the company's product layout and enhance market competitiveness.